Dexcom (NASDAQ: DXCM) and Pulse Biosciences (NASDAQ:PLSE) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability and earnings.
Volatility and Risk
Dexcom has a beta of -0.01, meaning that its stock price is 101% less volatile than the S&P 500. Comparatively, Pulse Biosciences has a beta of 1.89, meaning that its stock price is 89% more volatile than the S&P 500.
This table compares Dexcom and Pulse Biosciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent ratings for Dexcom and Pulse Biosciences, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Dexcom presently has a consensus price target of $74.50, suggesting a potential downside of 25.17%. Given Dexcom’s higher probable upside, research analysts clearly believe Dexcom is more favorable than Pulse Biosciences.
Institutional & Insider Ownership
9.0% of Pulse Biosciences shares are owned by institutional investors. 1.8% of Dexcom shares are owned by insiders. Comparatively, 39.3% of Pulse Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Dexcom and Pulse Biosciences’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Dexcom||$718.50 million||12.20||-$50.20 million||($0.58)||-171.66|
|Pulse Biosciences||N/A||N/A||-$25.56 million||N/A||N/A|
Pulse Biosciences has lower revenue, but higher earnings than Dexcom.
Dexcom Company Profile
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Pulse Biosciences Company Profile
Pulse Biosciences, Inc., a clinical-stage medical technology company, develops therapeutic tissue treatment platform based on its proprietary nano-pulse stimulation (NPS) technology. Its NPS is a non-thermal, precise, and focal drug-free tissue treatment technology that initiates cell death within treated tissue used in oncology, dermatology/aesthetics, minimally invasive, and veterinary applications. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was founded in 2014 and is headquartered in Hayward, California.
Receive News & Ratings for Dexcom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dexcom and related companies with MarketBeat.com's FREE daily email newsletter.